OGN Organon & Co.
Pharmaceutical Preparations · NYSE · SEC CIK 1821825 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.2%
TTM net income YoY-57.5%
TTM EPS YoY-59.2%
Revenue 3-yr CAGR-0.3%
Net income 3-yr CAGR-28.6%
Margins
Gross margin53.1%
Operating margin—
Net margin3.5%
FCF margin11.1%
EBITDA margin—
Returns
ROE20.3%
ROA1.6%
ROIC (approx.)—
Asset turnover0.45x
Leverage & solvency
Liabilities / assets91.1%
Debt / equity7.17x
Current ratio2.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.96x
Accruals ratio-4.7%
Payout ratio9.4%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B |
| Cost of revenue | $2.90B | $2.69B | $2.52B | $2.29B | $2.38B |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | $3.92B |
| R&D expense | $366.00M | $469.00M | $528.00M | $471.00M | $339.00M |
| SG&A expense | $1.72B | $1.76B | $1.89B | $1.70B | $1.67B |
| Interest expense | $504.00M | $520.00M | $527.00M | $422.00M | $258.00M |
| Pretax income | $425.00M | $807.00M | $673.00M | $1.12B | $1.53B |
| Income tax | $238.00M | -$57.00M | -$350.00M | $205.00M | $178.00M |
| Net income | $187.00M | $864.00M | $1.02B | $917.00M | $1.35B |
| EPS (basic) | 0.72 | 3.36 | 4.01 | 3.61 | 5.33 |
| EPS (diluted) | 0.72 | 3.33 | 3.99 | 3.59 | 5.31 |
| Dividends declared per share | 0.34 | 1.12 | 1.12 | 1.12 | 0.56 |
| Weighted avg. shares (diluted) | 260.76M | 259.15M | 256.27M | 255.17M | 254.19M |
| Balance sheet | |||||
| Cash & equivalents | $574.00M | $675.00M | $693.00M | $706.00M | $737.00M |
| Receivables | $1.33B | $1.36B | $1.74B | $1.48B | $1.38B |
| Inventory | $1.41B | $1.32B | $1.31B | $1.00B | $915.00M |
| Current assets | $4.35B | $4.35B | $4.51B | $3.93B | $3.76B |
| PP&E, net | $1.30B | $1.17B | $1.18B | $1.02B | $973.00M |
| Goodwill | $4.15B | $4.68B | $4.60B | $4.60B | $4.60B |
| Intangibles | $1.13B | $1.41B | $533.00M | $649.00M | $651.00M |
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | $10.68B |
| Current liabilities | $2.39B | $2.72B | $2.92B | $2.51B | $2.60B |
| Short-term debt | $16.00M | $20.00M | $9.00M | $8.00M | $9.00M |
| Long-term debt | $8.63B | $8.86B | $8.75B | $8.90B | $9.12B |
| Total debt | $8.64B | $8.88B | $8.76B | $8.91B | $9.13B |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | $12.19B |
| Shareholders' equity | $752.00M | $472.00M | -$70.00M | -$892.00M | -$1.51B |
| Net debt | $8.07B | $8.21B | $8.07B | $8.21B | $8.40B |
| Shares outstanding | 260.32M | 257.80M | 255.63M | 254.37M | 253.55M |
| Cash flow statement | |||||
| Operating cash flow | $700.00M | $939.00M | $799.00M | $858.00M | $2.16B |
| Capital expenditure | $162.00M | $175.00M | $251.00M | $196.00M | $192.00M |
| Free cash flow | $538.00M | $764.00M | $548.00M | $662.00M | $1.97B |
| Investing cash flow | -$390.00M | -$513.00M | -$260.00M | -$420.00M | -$481.00M |
| Financing cash flow | -$561.00M | -$368.00M | -$569.00M | -$433.00M | -$977.00M |
| Depreciation & amortization | $156.00M | $132.00M | $120.00M | $96.00M | $92.00M |
| Stock-based compensation | $77.00M | $105.00M | $101.00M | $75.00M | $59.00M |
| Dividends paid | $88.00M | $297.00M | $294.00M | $290.00M | $145.00M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.